IDEA Collider: Innovation & Asymmetric Learning in Pharma
ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.
· 42 min · Sezonul 3 Episodul 21
Note de episod
In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO 2026 and some of the key clinical datasets that could shape the next phase of oncology innovation.
Together, they discuss whether T-cell engagers can deliver transformative survival benefits in earlier lines of solid tumours with tarlatamab in DeLLphi-305; the promising science behind PD-1×VEGF combinations with Ivonescimab in HARMONi-GI1 and how we believe Merck & Co., Inc…
Site: ideacollider.simplecast.com
